CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013		Dec. 31, 2012
Current assets
Cash	$ 4,100,841		$ 534,046
Prepaid drug product for testing	148,301		195,000
Other current assets	49,713		42,575
Total current assets	4,298,855		771,621
Other assets
Technology licenses - related party	2,500,374		2,500,374
Less Accumulated Amortization	(1,048,700)		(928,231)
Intangible Assets, Net (Excluding Goodwill), Total	1,451,674		1,572,143
TOTAL ASSETS	5,750,529		2,343,764
Current liabilities
Accounts payable	43,578		57,000
Accounts payable - related party	0		8,582
Accrued expense	28,125		137,662
Accrued expense - related party	52,050		26,000
Accrued license payments - related party	50,000		100,000
Total current liabilities	173,753		329,244
Long term debt	0		0
TOTAL LIABILITIES	173,753		329,244
Shareholders' Equity
Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding	0		0
Common Stock, $.001 par value, 200,000,000 shares authorized 75,380,214 and 62,219,050 shares issued and outstanding as of 9/30/13 and 12/31/12, respectively	75,380		62,218
Additional paid in capital	16,888,167		13,321,075
Additional paid in capital for shares to be issued	3,220,967	[1]	762,510	[2]
Accumulated deficit during development stage	(14,607,738)		(12,131,283)
Total shareholders' equity	5,576,776		2,014,520
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY	$ 5,750,529		$ 2,343,764

[1] Represents 8,052,416 shares of common stock

[2] Represents 2,541,700 shares of common stock